Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment

Revista da Sociedade Brasileira de Medicina Tropical

Wilson Mayrink²  Ana Cristina De Carvalho Botelho²  Paulo Araújo Magalhães¹  Sebastião Mariano Batista²  Antonio De Oliveira Lima¹  Odair Genaro²  Carlos Alberto Da Costa¹  Maria Norma De Melo²  Marilene Susan Marques Michalick²  Paul Williams²  Magno Dias¹  Waleska Teixeira Caiaffa¹  Evaldo Do Nascimento²  George Luiz Lins Machado-coelho¹ 

[1] ,Universidade Federal de Minas Gerais Instituto de Ciências Biológicas Departamento de ParasitologiaBelo Horizonte MG

关键词: American cutaneous leishmaniasis;    Treatment;    Immunotherapy;    Leishmaniose tegumentar americana;    Tratamento;    Imunoterapia;   

DOI  :  10.1590/S0037-86822006000100003

来源: SciELO

【 摘 要 】

The first choice of treatment for American cutaneous leishmaniasis is the pentavalent antimonial drug. Although it has been shown that this treatment is mostly effective and indicated, some disadvantages should be taken into account such as side effects, long term treatment inconveniences and counter-indication for patients suffering from cardiopathy, nephropathy; yet, aging, pregnancy and other conditions. With the advent of the vaccine anti-American cutaneous leishmaniasis as a prophylactic measure, studies on therapy using the vaccine associated or not with other drugs have been performed by many investigators and it is currently among the alternative treatments and prevention measures for American cutaneous leishmaniasis. In conclusion, the association between antimony and vaccine (immunochemotherapy) showed the same cure rate when compared with the standard treatment (100%) and it was also able to reduce the salt volume in 17.9% and treatment length from 87 to 62 days, decreasing side effects.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License